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Abstract
MPV17 is described as a mitochondrial inner membrane channel. Although its function
remains elusive, mutations in the MPV17 gene result in hepato-cerebral mitochondrial DNA
depletion syndrome in humans. In this study, we show that MPV17 silencing does not
induce depletion in mitochondrial DNA content in cancer cells. We also show that MPV17
does not control cancer cell proliferation despite the fact that we initially observed a reduced
proliferation rate in five MPV17-silenced cancer cell lines with two different shRNAs. How-
ever, shRNA-mediated MPV17 knockdown performed in this work provided misguiding
results regarding the resulting proliferation phenotype and only a rescue experiment was
able to shed definitive light on the implication of MPV17 in cancer cell proliferation. Our
results therefore emphasize the caution that is required when scientific conclusions are
drawn from a work based on lentiviral vector-based gene silencing and clearly demonstrate
the need to systematically perform a rescue experiment in order to ascertain the specific
nature of the experimental results.
Introduction
MPV17 is a functionally elusive protein localized in the inner membrane of mitochondrion
and for which the encoding gene is located on chromosome 2p23-21 [1] [2] [3] [4]. MPV17
loss-of-function causes a rare autosomal recessive mitochondrial disorder called Mitochon-
drial DNA Depletion Syndrome (MDDS) marked by a highly reduced mitochondrial DNA
(mtDNA) copy number in affected tissues.
To date, there are 100 known individuals affected by one of the 48 describedMPV17 patho-
genic variants (approximately half of which are missense) [5]. The vast majority of these
patients (96%) suffer from the hepato-cerebral form of MDDS and exhibit a severe mtDNA
depletion in the liver (60–99% reduction). This is correlated with a decreased activity of respi-
ratory chain complexes. The onset of the disease takes place early in life (neonatal period/
infancy) and condemn the affected individual to a premature death due to liver dysfunction
progressing into liver failure. The remaining 4% of the patients suffer from a late-onset ence-
phalomyopathic disease with mild or no liver involvement [5].
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Although the current knowledge about MPV17 and its homologs have been recently
reviewed [6], the function of MPV17 is still obscure. There are evidence supporting that
MPV17 might be a channel with stress-dependent gating properties [7] [8] involved in nucleo-
tides homeostasis [9] [3] [10] [11] [12].
In a previous work, we found an increased expression ofMPV17 during stem cells hepato-
genic differentiation while performing a transcriptomic analysis in order to characterize the
mitochondrial biogenesis in this process ([13], data deposited in NCBI’s Gene Expression
Omnibus through GEO Series accession number GSE75184). Unexpectedly, we observed that
whileMPV17 silencing had no impact on hepatogenic differentiation, it significantly reduced
the proliferation of expanding Bone Marrow Mesenchymal Stem Cells (MSC) and Umbilical
Cord-MSC from different donors, suggesting a role of MPV17 in cell proliferation (unpub-
lished data). This is in accordance with the work of Choi and colleagues who showed that
MPV17 knockdown reduces the proliferation of NSC34 cells, a mouse motor neuronal cell line
[14]. As MPV17 has been implicated in stress response [15] [16] and has been described as a
channel with stress-dependent gating properties (oxidative and pH stress,. . .) [7], we then
wondered whether MPV17 could have a role in the proliferation of cancer cells or not, as they
inherently experience oxidative and metabolic stress.
In order to explore the putative role of MPV17 in the control of cancer cell proliferation, we
used a loss-of-function approach. Gene silencing and/or overexpression is generally the first
approach in order to investigate gene expression/function and lentiviruses are now widely
used to deliver transgenes that integrate into the host genome for gene expression tampering.
In this study, while demonstrating that MPV17 does not control neither cell proliferation nor
mtDNA content in cancer cells, our experimental results illustrate and emphasize the impor-
tance of carrying out a rescue experiment when working with shRNA-mediated knockdown.
Results
MPV17 is overexpressed in several tumours
Taking advantage of The Genome Cancer Atlas (TGCA) database, we show that the abun-
dance ofMPV17 transcript is significantly higher in tumours of 10 different tissues, including
liver, bile duct, and colon (Fig 1A). This is confirmed at the protein level by immunohis-
tochemistry staining performed on liver tumour biopsies from patients with adenocarcinoma
(Fig 1B).
MPV17 silencing is robustly associated with a decreased proliferation rate
in different cancer cell lines
In this study, we first assessed the effects of three commercially available shRNAs targeting
MPV17mRNA: sh129921, sh127649 and sh131038. Using western blot analysis, the efficiency
of gene silencing was evaluated by assessing the abundance of MPV17 in Huh7 cells trans-
duced with these three shRNA-encoding lentiviral vectors. Both sh129921 and sh127649 led to
an efficient knockdown of the gene while sh131038 did not efficiently induceMPV17 silencing
(Fig 2A).
We then demonstrated that Huh7 cells silenced forMPV17 with sh129921 and sh127649
displayed a severely decreased proliferation rate, as quantified by three different prolifera-
tion assays, namely the doubling time (Fig 2B), the MTT assay (Fig 2C), and the total pro-
tein content (Fig 2D). The reduced cell proliferation phenotype was correlated withMPV17
knockdown efficiency as no decreased proliferation rate was observed in Huh7 cells
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transduced with the vector encoding sh131038, the only shRNA that turned out to be ineffi-
cient in the knockdown induction.
To discard the possibility of a putative cell type or cancer type-specific phenotype, we
next assessed the impact of sh129921 on the proliferation of two other human hepatoma cell
lines, Hep3B and HepG2 cells, and two non-liver cancer cell lines, A549 cells, derived from
a human pulmonary adenocarcinoma and SQD9 cells, a human squamous cell carcinoma
cell line. Interestingly, Hep3B (Fig 2E), A549 (Fig 2F), SQD9 (Fig 2G) and HepG2 (data not
shown) cells transduced with sh129921-encoding vector also displayed a reduced prolifera-
tion phenotype.
MPV17 silencing is not associated with mtDNA copy number depletion
As MPV17 deficiency is associated with MDDS, we assessed whetherMPV17 silencing was
accompanied by depletion in the mtDNA content or not, possibly accounting for the associ-
ated decreased proliferation rate. However,MPV17 silencing did not lead to a reduction of
mtDNA content in any of the tested cancer cell lines (Fig 3). This result is in agreement with
the work of Dalla Rosa and collaborators who showed that proliferating fibroblasts from
MPV17-deficient patients do not display any reduced mtDNA content [9]. It is also in accor-
dance with the recent work of Alonzo and collaborators who did not find any reduction of
mtDNA content inMPV17-silenced HeLa cells [12].
The decreased proliferation rate inMPV17-silenced cells is associated with
a decrease in the abundance of ATF4
In order to determine the molecular mechanisms underlying the decreased proliferation
rate inMPV17-silenced cancer cells, a transcriptomic analysis was performed. The RNA
sequencing analysis was performed on Huh7 cells transduced with sh129921 or shNT-
encoding vectors. Among the differentially expressed genes, we focused on transcrip-
tional regulators potentially responsible for a reduced proliferation capacity. The activat-
ing transcription factor 4 (ATF4) frequently upregulated in cancer cells [17], was
Fig 1. Analysis of MPV17 expression in cancer tissues. The Cancer Genome Atlas (TCGA), a public platform allowing the analysis of gene expression
data sets generated by RNA sequencing (http://cancergenome.nih.gov), has been used to determine the expression level ofMPV17 in various tumour
tissues (T) versus healthy tissues (N). P values were calculated with the two-tailedWilcoxon signed rank Test (α = 5%; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001;
⇤⇤⇤⇤: p<0.0001; NS: not significant) (a). Detection of MPV17 by immunohistochemistry in a paraffin-embedded biopsy of a liver adenocarcinoma. A
strong signal for MPV17 is associated with the tumour, while the abundance of the protein is low in adjacent normal tissue (b).
https://doi.org/10.1371/journal.pone.0229834.g001
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downregulated inMPV17-silenced cells (Z-score = -2,792; P = 1,38E-14). It has been
shown that ATF4 not only up-regulates the expression of genes encoding actors impli-
cated in amino acid import and metabolism [18] [19] [20] but also promotes, indirectly,
purine synthesis [21], two essential aspects for cell proliferation. Based on this knowledge,
ATF4 was an attractive candidate in the attempt to elucidate the molecular mechanisms
underlying the reduced cell proliferation. The reduction of ATF4 transcript abundance
was confirmed at the protein level in sh129921 and sh127649-encoding vector transduced
Huh7 cells (Fig 4A) as well as in sh129921-encoding vector transduced Hep3B (Fig 4B)
and A549 (Fig 4C) cells, when compared with control cells transduced with shNT-con-
taining vector.
Altogether, these results seem to strongly support an involvement of MPV17 in cancer cell
proliferation asMPV17 silencing was consistently accompanied by a reduction of both cell
proliferation rate and ATF4 protein abundance.
Fig 2. Effect of shRNA-mediatedMPV17 knockdown on the proliferation of cancer cell lines.Huh7 cells were
transduced with non-target shRNA lentiviral vectors (shNT) or with shRNA lentiviral vectors targetingMPV17
expression (sh129921, sh127649, sh131038). Hep3B, A549 and SQD9 cells were transduced with lentiviral shNT-
encoding vectors or with sh129921-containing vectors. Cells were selected for 6 days with puromycin (2.5 μg/mL).
Cells were seeded at 8×103 cells/cm2 (a, b, c, d, Huh7; g, SQD9), 5×103 cells/cm2 (e, Hep3B) and 2.7×103 cells/cm2 (f,
A549) and grown for 4 days. MPV17 protein abundance was assessed by western blot analysis (a, Huh7). A
representative western blot of 3 independent biological replicates (2 for sh131038) is shown (left) along with the
western blot quantification of all the biological replicates (quantification with Image J software, data expressed as
relative protein abundance to cells transduced with shNT-encoding vectors, right). Proliferation was then assessed by
manual counting to calculate the doubling time (b, Huh7; e, Hep3B; f, A549; g, SQD9), by MTT assay (c, Huh7) and by
the total protein content (d, Huh7). Data are presented as mean ± S.E.M of 3 independent biological replicates (2 for
sh131038). P values were calculated with the one-tailed Mann-Whitney Test (α = 5%; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤:
p<0.001). Full blots are presented in S6 Fig.
https://doi.org/10.1371/journal.pone.0229834.g002
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MPV17 silencing is not always associated with a reduced proliferation
phenotype
Pursuing our analysis further, we observed that the sh129921-encoding vector transduced
Huh7 cells were able to adapt along the passages and progressively restored the proliferation
rate (Fig 5A), although MPV17 protein abundance was still strongly reduced (Fig 5B).
As we observed a recovery of the decreased proliferation rate over time, we therefore aimed
at generating an IPTG-inducible sh129921 model in Huh7 cells. Strikingly, while we observed
a strongMPV17 knockdown in this inducible expression model, with a silencing efficiency
Fig 3. Assessment of mtDNA content inMPV17-silenced cancer cell lines.Huh7 (a), Hep3B (b) and A549 (c) cells were transduced with non-target shRNA
lentiviral vectors (shNT) or with sh129921-containing vectors. Transduced cells were selected for 6 days with puromycin (2.5 μg/mL). DNA was then extracted
and mtDNA content was assessed by qPCR using NADH dehydrogenase 2 as a specific marker of mtDNA content and beclin for normalization with nuclear
DNA. Results are presented as means ± S.E.M of 3 independent biological replicates and are expressed in relative copy number to the nuclear DNA. P values
were calculated with the one-tailed Mann-Whitney Test (α = 5%; NS; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001).
https://doi.org/10.1371/journal.pone.0229834.g003
Fig 4. ATF4 protein abundance followingMPV17 knockdown in Huh7, Hep3B and A549 cells.Huh7 cells (a) were transduced with non-target
shRNA lentiviral vectors (shNT) or with shRNA lentiviral vectors targetingMPV17 expression (sh129921, sh127649, sh131038). Hep3B (b) and
A549 (c) cells were transduced with lentiviral shNT-encoding vectors or with sh129921-containing vectors. Cells were selected for 6 days with
puromycin (2.5 μg/mL) before assessing ATF4 protein abundance by western blot analysis. For each cell line, a representative western blot of 3 (2 for
sh131038) independent biological replicates is shown (left) along with the western blot quantification of all the biological replicates (quantification
with Image J software, data expressed as relative protein abundance to untranduced (unt) cells, right). P values were calculated with the one-tailed
Mann-Whitney Test (α = 5%; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001). Full blots are presented in S6 Fig.
https://doi.org/10.1371/journal.pone.0229834.g004
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comparable to the one observed in the constitutive silencing model (Fig 6A and 6B), the cell
proliferation rate was unchanged (Fig 6D). Moreover, ATF4 did not display a decreased pro-
tein abundance (Fig 6C).
This absence of effect ofMPV17 silencing on the cell proliferation rate in the inducible
expression system could have different origins. First, the IPTG molecule itself could have an
unexpected effect on Huh7 cells proliferation, even though IPTG is not known to be metabo-
lized [22]. Second, the reduced proliferation phenotype in the inducible expression system
might need more time to settle down. Indeed, in the constitutive system,MPV17 is silenced
for a total of 9 days before assessing the cell proliferation, as opposed to only 5 days in the
inducible model (see “Materials and Methods”, S1 Fig). A third difference between the two
approaches is that in order to ensure a proper knockdown ofMPV17 in the inducible model,
the culture medium was changed every day in order to renew the IPTG, as opposed to every
two or three days in the constitutive silencing model. One could thus hypothesize that this
daily medium renewal could prevent the settling of the reduced proliferation phenotype by
discontinuing the putative intercellular communication. These three hypotheses were tested
but failed to explain the different phenotypical outcomes observed for the constitutive or
inducible expression models (see S2 and S3 Figs).
These considerations led us to evaluate on Huh7 cells the effect of two additional commer-
cially available shRNAs, sh128669 and sh131201, targeting different regions of theMPV17
transcript (see S4 Fig). Both shRNAs strongly reduce the abundance of MPV17 protein (Fig
7A) but no significant effect on the proliferation rate was observed (Fig 7C, 7D and 7E). Also,
the abundance of ATF4 was not affected byMPV17 knockdown mediated by either sh128669
or sh131201 (Fig 7B). Thus, ATF4 reduced abundance correlates with the proliferation rate
but the putative link between the reduced proliferation phenotype (and therefore ATF4) and
MPV17 remains to be established.
In conclusion, we found that sh129921, sh127649, sh128669 and sh131201 all led to a strong
MPV17 knockdown while the resulting proliferation rates were highly variable. This lack of
consistency led us to suspect a putative involvement ofMPV17 isoforms that would be differ-
entially affected according to the shRNA used.
Fig 5. Evolution of Huh7 proliferation rate and MPV17 protein abundance in sh129921-mediatedMPV17 knockdown.Huh7 cells
were transduced with non-target shRNA lentiviral vectors (shNT) or with sh129921-containing vectors. Transduced cells were selected
for 6 days with puromycin (2.5 μg/mL). At 13 and 31 days after the transduction (PTD: post-transduction day), cells were seeded at
8×103 cells/cm2 and grown for 4 days. Proliferation was then assessed by manual counting to calculate the doubling time (a) and MPV17
protein abundance was analysed by western blot (b). P values were calculated with the one-tailed Mann-Whitney Test (α = 5%; NS; ⇤:
p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001). n = 3. Full blots are presented in S6 Fig.
https://doi.org/10.1371/journal.pone.0229834.g005
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Therefore, we next interrogated the Genotype-Tissue Expression (GTEx) Consortium
(2008, NIH) portal, that inventories the impact of genetic variations on gene expression within
major tissues in the human body from post mortem donors. The GTEx Portal proposes 22
MPV17 isoforms, including two major ones i.e. a short predominant isoform and a long one
(see S5 Fig). This long isoform referenced in RefSeq as NM002437.5 encodes the MPV17 pro-
tein that we detected on western blot while the translation of all the otherMPV17 isoforms is
not experimentally demonstrated. However, among the 22 isoforms, we observe that all the
transcripts targeted by sh129921 (1, 2, 3, 12, 13, 14, 15, 16 and 18) are also targeted by either
sh128669 (15, 16) or sh131201 (1, 18) or both (2, 3, 12, 13, 14). The same kind of observation
stands for the transcripts targeted by sh127649 (1, 2, 3, 5, 12, 13, 14, 15, 16, 18, 19, 21), provid-
ing no clear explanation about the opposite proliferation phenotypes observed for each pair of
shRNAs (sh129921/sh127649 versus sh128669/131201) (see S5 Fig).
Altogether, the absence of effect of the inducible sh129921 on the cell proliferation rate,
combined with the observation that, at least, two different shRNAs targetingMPV17
(sh131201 and sh128669) have no effect on the proliferation of Huh7 cells, despite a strong
Fig 6. MPV17 and ATF4 abundances and Huh7 cells proliferation rate following inducible sh129921-mediatedMPV17 knockdown.Huh7 cells were
transduced, or not (Unt), with inducible sh129921 lentiviral vector. Transduced cells were selected for 6 days with puromycin (2.5 μg/mL). Cells were then
incubated for 5 days in the presence of 0.1 mM of IPTG to induceMPV17 silencing. Cells were seeded at 8×103 cells/cm2 and grown for 4 days in daily
renewed medium containing IPTG. RNA was extracted and RT-qPCR was performed to assessMPV17 transcript level (data expressed relatively to
respective control (Ctl), n = 3) (a). MPV17 (b) and ATF4 (c) protein abundances were also assessed by western blot analysis after 5 days (MPV17) and 9
days (MPV17; ATF4) of IPTG induction. For each protein, a representative western blot of 3 independent biological replicates is shown (left) along with the
western blot quantification of all the biological replicates (quantification with Image J software, data expressed as relative protein abundance to respective
controls (Ctl) for MPV17 and untransduced (unt) cells for ATF4, right). Proliferation was then assessed by manual counting to calculate the doubling time
(d). As a comparison, we performed at the same time and on the same cells a similar experiment with the constitutive expression of sh129921 (mediating
MPV17 knockdown) as described in S1 Fig. P values were calculated with the one-tailed Mann-Whitney Test (α = 5%; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001).
Full blots are presented in S6 Fig. n = 3.
https://doi.org/10.1371/journal.pone.0229834.g006
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decrease in the MPV17 protein abundance, suggest that the decreased proliferation rate of
transduced cells observed for two shRNAs (sh129921 and sh127649) is not related to a reduced
MPV17 protein abundance. In an attempt to shed light on this question, we eventually per-
formed a rescue experiment.
Rescuing MPV17 does not restore the proliferation phenotype. As Huh7 cells could
neither be efficiently transfected nor transduced with theMPV17-expressing vector, HepG2
cells were used for the rescue attempt. Indeed, as mentioned before, we also observed the
reduced proliferation rate in this hepatoma cell line silenced forMPV17. This cell line turned
out to be the most receptive to the lentiviralMPV17-expressing vector. Since a rescue experi-
ment consists in re-introducing the shRNA-mediated silenced mRNA, it requires the use of a
shRNA targeting the 30UTR of the targeted mRNA. Thus, the reintroduced transcript that
lacks 30UTR is not affected by the shRNA.
We decided to performMPV17 overexpression before inducing the constitutive knock-
down mediated by sh129921. The justification of this chronology resides in the observation
that, on the contrary to shNT-encoding vector transduced cells, sh129921-encoding vector
transduced cells were not able to stand a second round of transduction due to cell death. This
suggests thatMPV17-silenced cells are distressed, in accordance with their decreased prolifera-
tion rate. This aspect is therefore not compatible with a short-term assessment of cell
proliferation.
MPV17 knockdown was properly induced in the overexpression control. Indeed, cells dou-
ble transduced with pLenti GFP, as a control, and then with pLKO.1 sh129921, displayed a
strong reduction of MPV17 abundance accompanied by the decreased proliferation rate (Fig
8A, 8B and 8C). As expected, the reduced proliferation phenotype was absent in pLenti GFP
Fig 7. Effect ofMPV17-targeting sh128669 and sh131201 on Huh7 cells proliferation, MPV17 and ATF4 protein abundances. Cells were
transduced with non-target shRNA lentiviral vectors (shNT) or with shRNA lentiviral vectors targetingMPV17 expression (sh128669 and
sh131201). Transduced cells were selected for 6 days with puromycin (2.5 μg/mL). Cells were seeded at 8×103 cells/cm2 and grown for 4 days. The
abundance of MPV17 (a) and ATF4 (b) proteins was assessed by western blot analysis. For each protein, a representative western blot analysis of 3
independent biological replicates is shown (left) along with the western blots quantification of all the biological replicates (quantification with
Image J software, data expressed as relative protein abundance to cells transduced with shNT-encoding vectors (a, MPV17) or untranduced (unt)
cells (b, ATF4), right). Proliferation was then assessed by manual counting to calculate the doubling time (c), by MTT assay (d) and by the total
protein content (e) and data are presented as mean ± S.E.M (3 biological replicates). P values were calculated with the one-tailed Mann-Whitney
Test (α = 5%; NS; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001). Full blots are presented in S6 Fig.
https://doi.org/10.1371/journal.pone.0229834.g007
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and pLKO.1 shNT double-transduced cells (Fig 8B and 8C). Cells double-transduced with
pLenti MPV17 and pLKO.1 shNT suitably overexpressed MPV17 (Fig 8A). It is interesting to
emphasize the fact that MPV17 overexpression, on its own, has no significant effect on cell pro-
liferation (Fig 8B and 8C). This observation can be reconciled with the idea that MPV17 is
described as a channel. Thus, the qualitative state of MPV17 (open/closed) would be more rele-
vant than its quantitative state. Finally, cells double-transduced with pLenti MPV17 and
pLKO.1 sh129921 overexpressed MPV17 but lost the expression of the endogenous protein (Fig
8A). Remarkably, these cells exhibited the reduced proliferation phenotype (Fig 8B and 8C).
Discussion
In this work we studied the putative role of MPV17 in cancer cell proliferation. WhileMPV17
silencing did not lead to depletion of mtDNA content in the tested cancer cell lines, in accor-
dance with literature [9] [12], the resulting proliferation phenotypes associated withMPV17
shRNA-mediated knockdown were unsettling and inconclusive, leading us to perform a rescue
experiment that eventually excluded a role of MPV17 in cancer cell proliferation. The intrigu-
ing and somewhat misleading results we obtained during this investigation clearly demon-
strate the need to systematically perform a rescue experiment in order to ascertain the specific
nature of the experimental results.
In this work, we tested five shRNAs targetingMPV17. The highly variable phenotypical out-
comes in Huh7 cells led us to consider a putative contribution ofMPV17 transcript isoforms
or the possible existence of an off-target effect. Despite the fact that we did not find any corre-
lation between the shRNA-targetedMPV17 transcript isoforms and the proliferation pheno-
type, it is not sufficient to preclude this hypothesis as there is no guaranty that theMPV17
transcript isoforms spectrum described in GTEx portal in human healthy liver is conserved in
our model.
It is also interesting to note that the predictive alignment (BLAST, ncbi) of sh129921 and
sh127649 on the human transcripts did not highlight the putative existence of a shared off-tar-
get mRNA. Again, this observation is however not sufficient to exclude a putative off-target
effect as it could be taking place through separate effectors for each shRNA.
Fig 8. Effect of MPV17 rescue on the proliferation ofMPV17-silenced HepG2 cells. Cells were first transduced with pLenti GFP or pLenti MPV17 and
selected for 6 days with puromycin (2.5 μg/mL). Cells were then transduced with shNT or sh129921-encoding lentiviral vectors and let to recover for 5 days to
allowMPV17 silencing. Cells were then seeded at 1.5×104 cells/cm2 and grown for 4 days before assessing MPV17 protein abundance (a). A representative
western blot analysis of 3 independent biological replicates is shown (left) along with the western blots quantification of all the biological replicates
(quantification with Image J software, data expressed as relative protein abundance to cells transduced with shNT and GFP-encoding vectors, right). Cell
proliferation assessment by MTT assay was also performed at day 1 and day 4. The ratio day 4/day 1 is then calculated in order to correct any putative seeding
differences that could mask or mislead to a partial phenotype rescue (c). Micrographies were taken at the phase contrast microscope before adding the lysis
buffer for the MTT assay (b). Data are presented as mean ± S.E.M (3 biological replicates). P values were calculated with the one-tailed Mann-Whitney Test (α
= 5%; NS; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001). Full blots are presented in S6 Fig.
https://doi.org/10.1371/journal.pone.0229834.g008
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However, the most intriguing observation in this work was that the same shRNA, expressed
either constitutively or induced by IPTG, resulted in different effects on cell proliferation. The
emergence of the inducible lentiviral vectors, which enable a reversible and fine tuning of gene
knockdown, allows further characterization of gene function, a better ease in studying genes
for which knockdown ends up being too deleterious or lethal for the cell, as well as timeframe
selection in a developmental process [23]. In this study, we resorted to this tool to overcome
an apparent progressive compensation/adjustment of the cells followingMPV17 knockdown.
The transient nature of the inducible knockdown would theoretically prevent this compensa-
tion to settle. However, we unexpectedly observed that the constitutive and inducible
approaches led to different phenotypical outcomes, despite using the same shRNA sequence
(sh129921). An explanation to this observation could reside in the fact that the shRNA is
expressed at a higher level in the constitutive model. Indeed, it is recommended by Sigma
Aldrich to ensure a minimum of 70% knockdown in a constitutive model, before switching to
an inducible one. This recommendation reflects the risk of obtaining a less potent gene silenc-
ing with an inducible vector when compared to a constitutive one due to a lower shRNA
expression. In our experimental conditions, the observation that MPV17 knockdown at the
protein level was quite comparable in both expression models does not preclude a higher
expression of the shRNA in the constitutive expression system, which could either increase the
risk of off-targeting or favour a better targeting of some non codingMPV17 transcript
isoforms.
While most researchers are confident in their interpretation of a particular gene function
when a consistent phenotype is observed with at least two different shRNA sequences targeting
a transcript, we and others experienced that this is not sufficient and that a rescue experiment
is an all-encompassing insurance of the veracity of the scientific conclusions [24]. However, as
properly reported by Peretz and collaborators, “Rescue experiments are a good way to ensure
specificity and are being added to an increasing number of studies, although, based on a survey
of scientific literature, this is probably limited to less than 0.1% of studies” [24]. Our work
stresses the imperative necessity to perform a rescue experiment in each study carrying out
shRNA-mediated gene knockdown. Nevertheless, the benefit of a rescue experiment often
matches its technical complexity. In terms of limitations while performing a rescue experi-
ment, we can mention that the re-expression of the silenced gene, generally at a higher level
than the normal endogenous one, might, in itself, lead to undesired effects [24]. In addition,
the random integration of the vector can also lead to additional off-target effects. Although the
rescue experiment should undeniably be an indispensable control in every experiment based
on shRNA-induced knockdown, it is not totally dependable as the absence of rescue of a par-
ticular observed phenotype does not necessarily mean that the effect observed with the shRNA
was due to off-target effects. Indeed, in ideal circumstances, every splice variant targeted by the
shRNA should be restored in the rescue experiment, which might not always be realistic [24].
In this work, the reintroduction of the only knownMPV17-coding transcript refuted any role
of the protein in cancer cell proliferation.
In conclusion, our work demonstrates that MPV17 does not induce depletion of mtDNA
content in cancer cell lines and that MPV17 does not control their cell cycle/proliferation.
Importantly, in the future, rescue experiments should be a requirement in any study involving
shRNA in order to silence a gene and analyse its subsequent effects on a particular phenotype.
While the absence of rescue of the phenotype is not a strict indicator of aspecficity of the
results, the restoration of the phenotype surely is a strong argument in favour of the specificity
of any shRNA-induced phenotype of interest. Noteworhty, we believe that sh129921 requires
further investigation as its robust effect on cell proliferation of different cancer cell lines could
bring to light a promising actor that could be exploited in the fight against cancer.
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Materials and methods
Cell culture
Cells were grown in Dulbecco0s Modified Eagle0s Medium (DMEM) low glucose (Life technol-
ogies, #31885) for human hepatoma cell lines Huh7 and HepG2 or in DMEM high glucose
(Life technologies, #41965) for human renal embryonic cell line HEK293T, or in MEMGluta-
MAX-1 (Life technologies, #42360) for human pulmonary adenocarcinoma cell line A549 and
human squamous cell carcinoma cell line SQD9, or in Roswell Park Memorial Institute
medium 1640 (Life technologies, #21875) for human hepatoma cell line Hep3B, supplemented
with 10% foetal bovine serum (Life technologies, #10270) in a 5% CO2 humid atmosphere at
37˚C. SQD9 cells were obtained from UCL (Vanessa Bol, Woluwe, Belgium). Huh7 cells
(JCRB0403) were kindly provided by Prof. Sven Diederichs (DKFZ, Heidelberg, Germany).
HepG2 (ATCC, HB-8065) were kindly provided by Prof. Luc Bertrand (UCL, Woluwe, Bel-
gium). Hep3B were purchased from ATCC (HB-8064). A549 cells (ATCC, CCL-185) were
kindly provided by Dr Jacques Piette (ULg, Liege, Belgium). HEK293T were obtained from
ATCC (CRL-11268).
Lentivirus production
HEK293T were seeded at 4x106 cells in 75 cm2 culture flask (Corning, #430641U). The next
day, the DNAmixture and the lipofectamine solution were prepared separately. The DNA
mixture was composed of 0.4 μg of the envelope encoding vector pCMV-VSVG (Addgene,
#8454), 3.6 μg of the packaging vector psPAX2 (Addgene, #12260) and 4 μg of the expressing
plasmid (Table 1), in 240 μL of 5% opti-MEM (Invitrogen, #31985). The lipofectamine
Table 1. List of plasmids used for MPV17 silencing.
Vector Reference
pLKO.1-puro sh131201 Sigma-Aldrich
SHCLND-NM_002437
TRCN0000131201
pLKO.1-puro sh128669 Sigma-Aldrich
SHCLND-NM_002437
TRCN0000128669
pLKO.1-puro sh127649 Sigma-Aldrich
SHCLND-NM_002437
TRCN0000127649
pLKO.1-puro sh129921 Sigma -Aldrich
SHCLND-NM_002437
TRCN0000129921
pLKO.1-puro sh131038 Sigma-Aldrich
SHCLND-NM_002437
TRCN0000131038
pLKO.1-puro shNT Sigma-Aldrich
SHC016-1EA
pLKO-puro-IPTG-3xLacO sh129921 Sigma-Aldrich
09301606MN
TRCN0000129921
The vectors backbone and encoding shRNA are specified along with their references.
https://doi.org/10.1371/journal.pone.0229834.t001
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solution was composed of 16 μL of lipofectamine 2000 (Invitrogen, #11669) in 240 μL of 5%
opti-MEM. Both preparations were incubated for 5 min at room temperature, combined, incu-
bated for 30 min at room temperature and added in the flask. After 18 h, the medium was
renewed and at 48 h and 72 h post-transfection, the medium was collected and filtered on
0.45 μm steriflip (Millipore, SE1M003M00). Lentiviruses were titrated by Reverse Transcrip-
tion quantitative Polymerase Chain Reaction (RT-qPCR) according to manufacturer0s recom-
mendations (Lentivirus qPCR Titer Kit, Applied Biological Materials, LV900).
MPV17 silencing
Sub-confluent cells were transduced in presence of 60 μg/mL protamine sulphate (Sigma-
Aldrich, P4020). The next day, they were selected for 6 days with puromycin (Sigma-Aldrich,
P8833) at 2.5 μg/mL. Experimental timelines ofMPV17 silencing with the constitutive and
inducible vectors are detailed in S1 Fig. Briefly, for the constitutive silencing ofMPV17, cells
were transduced with different shRNA-encoding vectors (pLKO.1-puro shNT, sh127649,
sh128669, sh129921, sh131201, sh131038), selected as described above and let to recover for 2
days without puromycin. They were then seeded and allowed to grow for 4 days before assess-
ing the proliferation.
For the inducible silencing ofMPV17, cells were transduced or not with pLKO-puro-IPTG-
3xLacO encoding sh129921, selected as described above and let to recover for 2 days.MPV17
silencing was then obtained by incubation of the transduced cells in the presence of 0.1 mM of
IsoPropyl ß-D-1-ThioGalactopyranoside (IPTG) (Sigma-Aldrich, I6758), renewed daily for 5
days unless stated otherwise. Cells were then seeded and allowed to grow for 4 days in presence
of IPTG renewed daily (unless stated otherwise) before assessing the proliferation.
Proliferation assessment
Cell counting. Cells were seeded in 25 cm2 culture flask (Corning, #430639) and grown
for 4 days. Cells were rinsed with Phosphate Buffered Saline (PBS) pH 7.4, trypsinized with
0.05% trypsin-EDTA (ThermoFisher, 25300) and centrifuged for 5 min at 200 g. The pellet
was resuspended in culture medium and cell suspension density was counted in a Neubauer
chamber. Doubling time was calculated as follow: time⇤ln(2) / (ln(number of cells at the end of
the experiment)—ln(number of seeded cells)).
MTT assay. Cells were seeded in 24-well culture plates (Corning, #3524), grown for 4
days and incubated for 1 h with 500 μL of tetrazolium dye MTT (Sigma-Aldrich, M2128)
(2.5 μg/mL in PBS) at 37˚C. Cells were then lysed for 1 h in lysis buffer (9% sodium dodecyl
sulphate, 60% N, N-dimethylformamide, pH 4.7), and absorbance was measured with a spec-
trophotometer (xMark, Bio-Rad) at 570 nm.
Protein content: Folin protein assay. Cells were seeded in 24-well culture plates (Corn-
ing, #3524), grown for 4 days and rinsed twice with PBS. The bovine serum albumin (VWR,
0332) protein standards and samples were incubated 30 min in presence of 200 μL of 0.5 M
sodium hydroxide, then 10 min with 750 μL of a solution A (1.96% sodium carbonate, 0.02%
sodium and potassium tartrate and 0.01% copper sulphate) and finally 30 min with 75 μL of
Folin and Ciocalteu0s phenol reagent (Sigma-Aldrich, F9252) diluted twice in distilled water.
Absorbance was measured with a spectrophotometer (xMark, Bio-Rad) at 740 nm [25].
Cell lysates and pierce protein assay
Cells were seeded in 75 cm2 culture flask (Corning, #430641U), rinsed once with PBS and
lysed with radioimmunoprecipitation assay buffer (20 mM tris hydroxymethyl, 150 mM
sodium chloride, 1 mM EDTA, 1 mM EGTA, 1% sodium deoxycholate, 10% glycerol, 1%
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NP40, pH 7.6) supplemented with protease inhibitor cocktail (Sigma-Aldrich, 11697498001)
and phosphatase inhibitor buffer (25 mM sodium orthovanadate, 250 mM 4-nitrophenylpho-
sphate, 250 mM ß-glycerophosphate, 125 mM sodium fluoride). Lysates were sonicated 3 x 10
sec (amplitude 50) and centrifuged (10 min, 15000 g). Cleared cell lysates were assessed for
protein content with Pierce 660 Protein Assay Reagent (ThermoFisher, 22660) according to
the manufacturer0s recommendations.
Western blotting analysis
Amounts of 20 μg of protein samples were prepared in loading buffer (0.03 M Tris-hydrochlo-
ride acid; pH 6.8, 0.04 M sodium dodecyl sulphate, 0.4 M β-mercaptoethanol, 5% glycerol,
0.15 mM bromophenol blue), boiled for 5 min, resolved on polyacrylamide gel and transferred
on a nitrocellulose membrane (Bio-Rad). Membrane was blocked for 1 h at room temperature
in Odyssey Blocking Buffer (OBB) (LI-COR, P/N 927) diluted twice in PBS and incubated
overnight at 4˚C with the primary antibody diluted in OBB with 0.1% Tween-20 (OBB-T). For
MPV17 detection, membrane was treated prior to blocking step with Super Signal Western
Blot Enhancer (ThermoFisher, 46640) according to the manufacturer0s recommendations.
The next day, membrane was rinsed 3 x 5 min in PBS with 0.1% Tween-20 (PBS-T), incubated
with secondary antibody diluted in OBB-T 0.1% for 1 h at room temperature, rinsed 3 times in
PBS-T 0.1%, dried and scanned with the Odyssey Infrared Imager (LI-COR, 9120). For the
description of the antibodies used in this study, see Table 2.
Construct for MPV17 overexpression
MPV17 mRNA was reverse transcribed (Transcriptor First Strand cDNA kit, Roche,
04379012001) using a specific primer (50-AGGTGGAAACGATGGAGTGA-30). A PCR was then
Table 2. List of antibodies and their dilutions used for western blotting.
Antibody Reference Dilution
Anti-MPV17 Proteintech 1/1000
10310-1-AP
Anti-ATF4 Santa Cruz 1/1000
Sc-390063
Anti-ATF4 Cell Signaling 1/1000
#11815 lot 3
Anti-tubulin Sigma-Aldrich 1/10000
T5168
Anti -actin Sigma-Aldrich 1/10000
A5441
Anti-GAPDH Abcam 1/10000
128915
Anti-rabbit IgG LI-COR 1/10000
IRDye 800CW Goat 926–32211
Anti-mouse IgG LI-COR 1/10000
IRDye 680RD Goat 926–68070
Anti-rabbit IgG LI-COR 1/10000
IRDye 680RD Goat 926–68071
Anti-mouse IgG LI-COR 1/10000
IRDye 800CW Goat 926–32210
The antibodies used for the western blot analysis are specified with their reference and working dilutions.
https://doi.org/10.1371/journal.pone.0229834.t002
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performed using a forward primer containing a restriction site for BamH1 (F: 50-AGGATCCA
GGAAGCATGGCA-30) and a reverse primer containing a restriction site for Sal1 (R: 50-AGT
CGACGGCAGGCTTAGA-30). PCR products were purified using Wizard SV Gel and PCR
Clean-Up System (Promega, A9281). An amount of 1 μg of PCR product and pLenti PGK
GFP Puro (Addgene, #19070) was digested with BamH1, purified, restricted with Sal1, purified
and finally ligated with T DNA ligase (Biolabs, M0202S) to construct the pLenti PGKMPV17
Puro plasmid.
Rescue experiment
HepG2 cells were transduced with pLenti PGK GFP puro or pLenti PGKMPV17 puro-con-
taining lentiviruses and selected for 6 days with puromycin (2.5 μg/mL). Cells were then trans-
duced with PLKO.1-puro vector constitutively encoding sh129921 or shNT (Table 1). Cells
were then allowed to recover and generateMPV17-targeting shRNA for 5 days, seeded and
allowed to grow for 4 days. Cell proliferation was assessed by MTT assay at day 1 and day 4. To
overexpress MPV17, we usedMPV17-silencing andMPV17-overexpression vectors that were
both bearing the resistance to puromycin. This obviously constitutes an obstacle in the selec-
tion of the cells that are double transduced. However, we decided to proceed further based on
the knowledge that the sh129921-encoding vector robustly led to a very efficient transduction
rate (nearly 100%), therefore allowing to bypass the need for an ensuing antibiotic selection.
mtDNA content determination
DNA was extracted with the Wizard Genomic DNA Purification Kit (Promega, A1120)
according to the manufacturer0s recommendations. qPCR for mtDNA amplification was per-
formed on the gene encoding ND2 (NADHDehydrogenase 2) using the forward primer 50-
TGTTGGTTATACCCTTCCCGTACTA-30 and the reverse primer 50-CCTGCAAAGATGGTA-
GAGTAGATGA-30. For the normalization with nuclear DNA, the gene encoding Beclin was
amplified with the forward primer 50-CCCTCATCACAGGGCTCTCTCCA-30 and the reverse
primer 50- GGGACTGTAGGCTGGGAACTATGC-30. Real time PCR was performed with
SYBR Select Master Mix (ThermoFisher, 4472908). mtDNA copy number was calculated
according to the following formula: 2⇤2^-ΔCt (where ΔCt = Ctmean ND2 –Ctmean Beclin).
RNA extraction and RT-qPCR
RNA was extracted with RNeasy Mini kit (Qiagen, 74104) according to manufacturer0s recom-
mendations and QIAcube (Qiagen). RT was performed with GoScript™ Reverse Transcription
Mix (Promega, A2791) according to the manufacturer0s recommendations. qPCR was per-
formed with SYBR Select Master Mix (ThermoFisher, 4472908). We used the 2-ΔΔCt method to
assess the relative mRNA expression. TheMPV17 primers used in this study are the following:
F: GCTCAGGAAGCATGGCACTCT; R: AATGTCACCCAGGCCCATCA.
RNA sequencing
Huh7 cells were transduced with shRNA non-target lentiviral vector (shNT) or with shRNA
vector constitutively targetingMPV17 expression (sh129921). RNA quality was analysed with
the Bioanalyzer 2100 (Agilent). RNA samples (n = 4) were sent to Genomic Core Leuven (Bel-
gium) for RNA sequencing and data were analysed with Ingenuity Pathway Analysis (QIA-
GEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).
PLOS ONE MPV17 does not control cancer cell proliferation
PLOS ONE | https://doi.org/10.1371/journal.pone.0229834 March 10, 2020 14 / 18
Immunohistochemistry
Slices were incubated 2 x 5 min in xylene (ThermoFisher, X/0200/21), 2 x 3 min in isopropanol
(VWR, 20842.330) and 10 min in 1% H2O2 (VWR, 23.613.446) / methanol prepared extempo-
raneously. Slices were washed 3 min in tap water and 3 min in demineralized water. Slices
were then incubated 30 min in the 98˚C water bath with the “Target Retrieval Solution 1X” pH
6.1 (Dako, S169984-2) and let to cool down for 15 min at room temperature. Slices were
washed 5 min in tap water, 2 x 3 min in PBS and incubated 1 h at room temperature with a
solution of PBS-2% Normal Goat Serum (NGS) (ThermoFisher, 16210064). Slices were then
incubated with the primary antibody anti-MPV17 (Table 2) diluted 1/100 in a solution of PBS-
0.5% NGS, overnight at 4˚C. Slices were washed 3 x 3 min in PBS-T 0.05% baths and 3 min in
PBS. Slices were then incubated 30 min at room temperature with the secondary antibody
EnVision-HRP anti-rabbit (Dako, K400311). Slices were washed 3 x 3 min in PBS-T 0.05%
and 3 min in PBS. Slices were then incubated 4 min at room temperature in the DAB solution
(Dako, K346811) and washed 5 min in running tap water. Slices were incubated 5 min in
Mayer Hematoxyline and washed 5 min in running tap water. Slices were finally incubated 3x
3 min in isopropanol, 3x 3 min in xylene and mounted on coverslip with Entallan glue.
Statistical analysis
Data are expressed as the mean ± Standard Error of the Mean (S.E.M). Figure plotting was per-
formed with Prism software. Statistical analysis was performed using a one-tailed Mann-Whit-
ney Test or a two-tailed Wilcoxon signed rank Test (α = 5%; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤:
p<0.001; ⇤⇤⇤⇤: p<0.0001).
Supporting information
S1 Fig. Experimental timelines ofMPV17 silencing in the constitutive and inducible mod-
els. Cells were transduced and puromycin-selected with a vector allowing a constitutive (a) or
an inducible (b)MPV17 silencing. After 2 days of recovery, cells were either seeded and
allowed to grow for 4 days before assessment of proliferation (a) or treated with 0.1 mM of Iso-
Propyl ß-D-1-ThioGalactopyranoside (IPTG) for 5 days to induceMPV17 silencing prior to
the seeding (b). The proliferation was then assessed after 4 days of growth in presence of IPTG
renewed daily.
(PPTX)
S2 Fig. Effect of IPTG on Huh7 cells proliferation following constitutive sh129921-me-
diatedMPV17 knockdown.Huh7 cells were transduced with non-target shRNA lentiviral
vectors (shNT) or with sh129921-containing vector. Transduced cells were selected for 6 days
with puromycin (2.5 μg/mL). Cells were seeded at 8×103 cells/cm2 and grown for 4 days in the
presence or in the absence of 0.1 mM of IPTG. To mimic the conditions found in the inducible
model of expression, the IPTG-containing medium was renewed daily. We therefore included
a control in which no IPTG was present while the medium was also changed every day (Ctl).
Data are presented as mean ± S.E.M (3 biological replicates). P values were calculated with the
one-tailed Mann-Whitney Test (α = 5%; NS; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤: p<0.001).
(PPTX)
S3 Fig. Effect of the duration of IPTG pre-treatment and of the medium change frequency
on Huh7 cells proliferation in response to inducible sh129921-mediatedMPV17 knock-
down. Cells were transduced, or not (Unt), with inducible sh129921 lentiviral vectors and
selected for 6 days with puromycin (2.5 μg/mL). Cells were then incubated for 14 days in the
presence of 0.1 mM of IPTG to induceMPV17 silencing and culture medium was changed
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daily (a, b, c) or every 2 days (c, d, e). Cells were seeded at 8×103 cells/cm2 and grown for 4
days in presence of IPTG in the same conditions. MPV17 protein abundance was assessed by
western blot analysis (a, d) and quantified with Image J software (b, e). Proliferation was then
assessed by manual counting to calculate the doubling time (c, f). Full blots are presented in S6
Fig. Data are presented as mean ± S.E.M of 3 independent biological replicates. P values were
calculated with the one-tailed Mann-Whitney Test (α = 5%; NS; ⇤: p<0.05; ⇤⇤: p<0.01; ⇤⇤⇤:
p<0.001).
(PPTX)
S4 Fig. Localisation of the shRNA-targeted sites onMPV17 transcript. The effects of several
commercially available shRNAs directed againstMPV17 transcript were assessed in Huh7
cells. Each shRNA Sigma Aldrich reference (sh128669, sh131201, sh131038, sh127649 and
sh129921) is indicated above its target site. Each grey box represents an exon ofMPV17 tran-
script (NM002437.5). A line indicates the 30UTR and 50UTR ofMPV17 transcript.
(PPTX)
S5 Fig. Localisation of the shRNA-targeted sites on theMPV17 transcript isoforms refer-
enced in human liver. The Genotype-Tissue Expression (GTEx) Project was supported by the
Common Fund of the Office of the Director of the National Institutes of Health, and by NCI,
NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analysis described in this
manuscript and this Fig. were obtained from the GTEx Portal on 02/05/19. We indicated the
Sigma Aldrich reference of each shRNA targetingMPV17 transcripts (sh128669, sh131201,
sh131038, sh127649 and sh129921) above its targeted site. Each box represents an exon in
MPV17 transcript isoforms. The darker the purple, the more abundant the transcript (as
referred by Log 10 (TPM)). The 30UTR is located on the left of the image, and the 50UTR on
the right. We added an asterisk (⇤) that indicates both shRNAs providing the reduced prolifer-
ation phenotype, while ø indicates both shRNAs leading to an unchanged proliferation rate.
(PPTX)
S6 Fig. Full-length blots of the cropped blots presented in this work. Protein immunostain-
ing was performed with secondary antibodies coupled to infrared dyes (IRDye; green: 800nm/
red: 700 nm). a: Full blot of the one presented in Figs 2A and 7A; b: Full blot of the one pre-
sented in Figs 4A and 7B (Anti-ATF4 from Santa Cruz); c: Full blot of the one presented in Fig
8A; d: Full blot of the one presented in Fig 4C (Anti-ATF4 from Cell Signaling); e: Full blot of
the one presented in Fig 4B (Anti-ATF4 from Cell Signaling); f: Full blot of the one presented
in Fig 5B; g: Full blot of the one presented in Fig 6B; h and i: Full blots of the ones presented in
S3 Fig; j: Full blot of the one presented in Fig 6C (Anti-ATF4 from Santa Cruz).
(DOCX)
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